Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $93.3 million.

  • Entrada Therapeutics' Cash & Equivalents rose 1952.24% to $93.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.3 million, marking a year-over-year increase of 1952.24%. This contributed to the annual value of $101.2 million for FY2024, which is 4971.6% up from last year.
  • As of Q3 2025, Entrada Therapeutics' Cash & Equivalents stood at $93.3 million, which was up 1952.24% from $72.5 million recorded in Q2 2025.
  • Over the past 5 years, Entrada Therapeutics' Cash & Equivalents peaked at $227.6 million during Q1 2023, and registered a low of $45.2 million during Q4 2022.
  • Its 4-year average for Cash & Equivalents is $91.2 million, with a median of $78.0 million in 2024.
  • In the last 5 years, Entrada Therapeutics' Cash & Equivalents soared by 16896.03% in 2023 and then crashed by 6993.78% in 2024.
  • Entrada Therapeutics' Cash & Equivalents (Quarter) stood at $45.2 million in 2022, then surged by 49.7% to $67.6 million in 2023, then soared by 49.72% to $101.2 million in 2024, then fell by 7.83% to $93.3 million in 2025.
  • Its Cash & Equivalents stands at $93.3 million for Q3 2025, versus $72.5 million for Q2 2025 and $67.8 million for Q1 2025.